<p>QYUNS-B (02509.HK) announced its 2025 annual results, with revenue of 807 million RMB, an increase of 408.2% year-on-year. It recorded a net profit of 314 million RMB, turning from a loss of 336 million RMB in the previous year; earnings per share were 1.41 RMB. No final dividend was declared</p>

159102

159837

159849

<p>QYUNS-B announced its 2025 annual performance, with revenue of 807 million RMB (same below), an increase of 408.2% year-on-year. It recorded a net profit of 314 million RMB, compared to a loss of 336 million RMB in the previous year, turning from loss to profit; earnings per share were 1.41 RMB. No final dividend will be distributed</p>

AASTOCKS

Huaan Hang Seng Biotech ETF

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

QYUNS-B

"Performance" QYUNS's annual net profit is 314 million RMB, turning losses into profits